New York, Feb 17, 2026, 11:16 EST — Regular session.
- JNJ shares slipped roughly 0.2% during late-morning trading, underperforming a modestly weaker U.S. market.
- The FDA has cleared a new, simplified once-a-month dosing regimen for Rybrevant Faspro in EGFR-mutated lung cancer patients.
- Near-term positioning may shift ahead of next week’s ex-dividend date.
Johnson & Johnson slipped around 0.2% to $242.92 late Tuesday morning. Shares changed hands between $242.20 and $244.56 earlier in the session.
The company announced U.S. FDA approval for a streamlined once-monthly dosing regimen of Rybrevant Faspro, its subcutaneous form of amivantamab, for certain patients with EGFR-mutated advanced non-small cell lung cancer using Lazcluze. It said patients are eligible to switch to monthly dosing starting as soon as week five. 1
Why it matters now: J&J is counting on oncology and MedTech for growth, and doctors often weigh dosing convenience when picking a treatment. According to a Phase 2 update cited by OncLive, more than 80% of previously untreated patients responded to the monthly schedule. 2
“A monthly dosing schedule offers patients convenience without sacrificing efficacy,” said Danny Nguyen, assistant clinical professor at City of Hope and a principal investigator on the related studies. Mahadi Baig, J&J’s vice president of U.S. medical affairs, described the move as a step toward “the simplest and fastest” combination therapy for this setting. 3
The stock barely budged, mirroring losses across U.S. equities as traders dumped some risk plays and big indexes lost ground in early action. 4
Healthcare names drew attention after Medtronic topped estimates for the quarter, only to slide before the bell. The company maintained its full-year outlook, which took the shine off the earnings beat. Guidance, it turns out, can weigh as heavily as the numbers. 5
The FDA’s move for J&J amounts to a tweak in dosing rather than a green light for a new indication, so the market impact depends on how prescribing shakes out, what insurers are willing to cover, and whether doctors favor convenience enough to overlook side effects in the EGFR-mutated lung cancer space. If uptake lags, don’t expect the stock to react much; it could just track the broader market instead of the news.
Next up, investors have their eyes on J&J’s ex-dividend date—Feb. 24. The $1.30-per-share quarterly dividend is set for payment on March 10, per the company’s announcement. 6
